Tumor immunotherapy is only effective in a fraction of patients due to a low response rate
and severe side effects, and these challenges of immunotherapy in clinics can be addressed …

Since the first connection between Fenton chemistry and biomedicine, numerous studies
have been presented in this field. Comprehensive presentation of the guidance from Fenton …

Background The additive or synergistic sustained antitumour effect of immune checkpoint
inhibitors in combination with oxaliplatin-based chemotherapy has previously been …

Neutrophils accumulate in solid tumors, and their abundance correlates with poor prognosis.
Neutrophils are not homogeneous, however, and could play different roles in cancer …

DNA mismatch repair deficiency (MMRd) is associated with a high tumor mutational burden
(TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most …

Immune-checkpoint inhibitors and chimeric antigen receptor (CAR) T cells are
revolutionizing oncology and haematology practice. With these and other immunotherapies …

Conventional chemotherapeutics have been developed into clinically useful agents based
on their ability to preferentially kill malignant cells, generally owing to their elevated …

Recent years have witnessed increasingly rapid advances in nanocarrier-based
biomedicine aimed at improving treatment paradigms for cancer. Nanogels serve as …

Most spatial transcriptomics technologies are limited by their resolution, with spot sizes
larger than that of a single cell. Although joint analysis with single-cell RNA sequencing can …

T cell immunoglobulin and mucin-containing molecule 3 (TIM-3), first identified as a
molecule expressed on interferon-γ producing T cells, is emerging as an important immune …